Taurin S - Search Results

1

Raloxifene nanomicelles reduce the growth of castrate-resistant prostate cancer.

Pritchard T, Rosengren RJ, Greish K, Taurin S. Pritchard T, et al. Among authors: taurin s. J Drug Target. 2016;24(5):441-9. doi: 10.3109/1061186X.2015.1086360. Epub 2015 Sep 16. J Drug Target. 2016. PMID: 26373825

2

Mechanisms for the activity of heterocyclic cyclohexanone curcumin derivatives in estrogen receptor negative human breast cancer cell lines.

Somers-Edgar TJ, Taurin S, Larsen L, Chandramouli A, Nelson MA, Rosengren RJ. Somers-Edgar TJ, et al. Among authors: taurin s. Invest New Drugs. 2011 Feb;29(1):87-97. doi: 10.1007/s10637-009-9339-0. Epub 2009 Oct 9. Invest New Drugs. 2011. PMID: 19816657

3

Synthesis and cytotoxic potential of heterocyclic cyclohexanone analogues of curcumin.

Yadav B, Taurin S, Rosengren RJ, Schumacher M, Diederich M, Somers-Edgar TJ, Larsen L. Yadav B, et al. Among authors: taurin s. Bioorg Med Chem. 2010 Sep 15;18(18):6701-7. doi: 10.1016/j.bmc.2010.07.063. Epub 2010 Aug 1. Bioorg Med Chem. 2010. PMID: 20728364

4

RL71, a second-generation curcumin analog, induces apoptosis and downregulates Akt in ER-negative breast cancer cells.

Yadav B, Taurin S, Larsen L, Rosengren RJ. Yadav B, et al. Among authors: taurin s. Int J Oncol. 2012 Sep;41(3):1119-27. doi: 10.3892/ijo.2012.1521. Epub 2012 Jun 15. Int J Oncol. 2012. PMID: 22710975

5

Anticancer nanomedicine and tumor vascular permeability; Where is the missing link?

Taurin S, Nehoff H, Greish K. Taurin S, et al. J Control Release. 2012 Dec 28;164(3):265-75. doi: 10.1016/j.jconrel.2012.07.013. Epub 2012 Jul 16. J Control Release. 2012. PMID: 22800576 Review.

6

RL66 a second-generation curcumin analog has potent in vivo and in vitro anticancer activity in ER‑negative breast cancer models.

Yadav B, Taurin S, Larsen L, Rosengren RJ. Yadav B, et al. Among authors: taurin s. Int J Oncol. 2012 Nov;41(5):1723-32. doi: 10.3892/ijo.2012.1625. Epub 2012 Sep 11. Int J Oncol. 2012. PMID: 22971638

7

Curcumin-derivative nanomicelles for the treatment of triple negative breast cancer.

Taurin S, Nehoff H, Diong J, Larsen L, Rosengren RJ, Greish K. Taurin S, et al. J Drug Target. 2013 Aug;21(7):675-83. doi: 10.3109/1061186X.2013.796955. Epub 2013 May 16. J Drug Target. 2013. PMID: 23679865

8

Raloxifene reduces triple-negative breast cancer tumor growth and decreases EGFR expression.

Taurin S, Allen KM, Scandlyn MJ, Rosengren RJ. Taurin S, et al. Int J Oncol. 2013 Sep;43(3):785-92. doi: 10.3892/ijo.2013.2012. Epub 2013 Jul 10. Int J Oncol. 2013. PMID: 23842642

9

A novel role for raloxifene nanomicelles in management of castrate resistant prostate cancer.

Taurin S, Nehoff H, van Aswegen T, Rosengren RJ, Greish K. Taurin S, et al. Biomed Res Int. 2014;2014:323594. doi: 10.1155/2014/323594. Epub 2014 Feb 6. Biomed Res Int. 2014. PMID: 24689036 Free PMC article.

10

Nanomedicine for drug targeting: strategies beyond the enhanced permeability and retention effect.

Nehoff H, Parayath NN, Domanovitch L, Taurin S, Greish K. Nehoff H, et al. Among authors: taurin s. Int J Nanomedicine. 2014 May 22;9:2539-55. doi: 10.2147/IJN.S47129. eCollection 2014. Int J Nanomedicine. 2014. PMID: 24904213 Free PMC article. Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

68 results

Search Page

Filters